(BiotechEast staff)15 October, 2012 Taiwan Liposome Company (TLC), a specialty pharmaceutical company with proprietary drug delivery technology based on lipid formulation platforms, filed its IPO submission with GreTai jSecurities Market on Sep 25th, 11 months after its listing on the Emerging Market.TLC, with operations in Taipei, Taiwan; Leiden, The Netherlands; and South San Francisco, California is developing and commercializing a series of super generics, new formulations, and new chemical entities (NCE) drugs with advantageous delivery or formulation characteristics. Since its establishment in 1997, TLC has developed five lipid-based drug delivery system technology platforms and six products, ranging from pre-clinical to on market, with one of the super generics been licensed out to Teva early 2012, proving the company's competitiveness in the international arena.TLC also received some good news recently in the field of NCE, having its multi-mechanism anti-cancer NCE drug "Lipotecan® selected by TFDA (Taiwan's drug approval body) as one of the priority projects for the newly initiated "Cross-Strait Research and Development Collaboration Program", this program is designed to help consolidate the drug review process between China and Taiwan, to thus speed up the approval process. Lipotecan® is currently in Phase II clinical trial, showing favorable results in tumor control for HCC (Hepatocellular Carcinoma) patients.TLC is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of cancer, ophthalmic conditions, and infectious diseases. TLC founded and led by renowned scientist, Dr. Keelung Hong, who has over 30 years of research and development experience in liposomes with over 100 publications.
Posts
No comments:
Post a Comment